Omnicell Lifts 2026 Earnings Outlook Despite Memory-Cost Pressure
Higher guidance follows operating efficiencies, while memory-chip costs and lengthy customer approvals may slow Titan XT sales.
Key takeaways
- Omnicell raised its 2026 EBITDA and earnings-per-share guidance after its second-quarter results.
- A one-time $15 million tariff refund contributed to second-quarter EBITDA of $67 million.
- Memory-chip costs are expected to add about $6 million in the second half of 2026.
Omnicell raised its 2026 outlook for non-GAAP EBITDA and earnings per share after second-quarter results benefited from cost control and operating efficiency. The company now expects EBITDA of $175 million to $185 million and earnings per share of $2.15 to $2.30.
Second-quarter non-GAAP EBITDA was $67 million, including a one-time $15 million tariff refund. Excluding the refund, EBITDA was $52 million, which Omnicell said was still above the midpoint of its prior guidance.
Customer engagement around enterprise medication management remained high in the quarter, management said, and the product-bookings pipeline was larger than in recent years. Interest focused on Titan XT and the OmniSphere platform, which is designed to connect the company’s products and workflows.
Cost pressures remain a risk. Omnicell expects memory-chip supply constraints to add about $6 million in costs during the second half of 2026. It expects the impact to reduce full-year consolidated gross margin by about 50 basis points.
Titan XT sales may also take time to develop. The company said its current XT installed base is younger than the G Series base was during an earlier transition, while customer approval of large capital projects can take quarters or years. Titan XT is scheduled to ship in the second half of 2026.
This article was produced with the help of AI technology. Source: Yahoo Finance
